About Us     Lung Cancer Test - CPC001     Technology Platform     About Lung Cancer     Contact Us
Lung Cancer Test - CPC001

CPC has developed the CPC001 test, a plasma based test for the early detection of non-small cell cancer (NSCLC). CPC researched and analyzed over one hundred biomarkers in a series of trials totaling over two thousand patients and has identified fifteen biomarkers that distinguish early stage NSCLC from normal specimens with high degree of Sensitivity, Specificity, Accuracy, and Positive Predictive Value.

The CPC001 test is a qualitative plasma test that combines the results of fifteen biomarkers and selected demographic information into a single score. The single score is either a yes/no for the presence of early stage NSCLC. The test is indicated for subjects who are at a high risk of developing NSCLC, such as smokers over the age of forty five. Initially the CPC001 will be used as an adjunctive diagnostic test when the primary diagnostic test, i.e., a CT Scan reveals nodules in the lungs that are unclear to the physician as to whether the nodule is cancerous or not. After sufficient clinical data is collected and approved by the regulatory Agency, CPC001 may be offered as a screening or a stand-alone diagnostic test.

105 Washington St. • Michigan City, Indiana 46360